BAXTER INTERNATIONAL INC (BAX): what the price requires

The current priced-in claim for BAXTER INTERNATIONAL INC (BAX) is temporarily suppressed because the live engine record is unavailable. The dated report remains a snapshot, not a current market read.

Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/BAX

Headline

FieldValue
TickerBAX
CompanyBAXTER INTERNATIONAL INC
Current price$22.40/sh
CompositionInfusion Therapies & Technologies 36% / Advanced Surgery 11% / Care & Connectivity Solutions 17% / Front Line Care 10% / Injectables & Anesthesia 12% / Drug Compounding 10% / Other 3%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin needed8.3%
Operating margin (mid-cycle)13.5%
Margin compression implied-5.2pp
Trailing margin (depressed year)4.4%
Multiple paid13x mid-cycle operating income

The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.

The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.

Solve inputs: computed at a 7% cost of capital with 4% terminal growth over a 5-year stage (computed at the 7% minimum rate; the CAPM rate 6.1% sits below it).

Reconcile: at the x-ray's 9.3% required return this reads ~3.3%/yr; the models below use their own rates.

How unusual the bet is: within-range

ReferenceValue
vs own history+0.42σ
cohort percentile (of 112 peers)20
implied end-window share0%

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset2.01x2expensive
Earnings2.69x3expensive
Relative0.25x3justifies
Growth0.81x3justifies

Families that justify the price: Relative, Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 4.9%); the inversion above states its own rate.

Per-Model Detail (n=11)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$33.280.67xyesFCF base $1.3B, growth -3% (input: historical growth), terminal g 0.5%, WACC 4.9%, 5yr projection
DCF Exit MultipleGrowth$27.500.81xyesExit EV/EBITDA: 27.6x / 29.6x / 31.6x (bear / base = today's held flat / bull), 5yr
Relative ValuationRelative$87.920.25xyesP/S fallback (negative EPS): Sector P/S 4.0x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$11.791.90xyesReference only (book value floor): BV/sh $11.79, ROE negative
Two-Stage Excess ReturnAsset$10.612.11xyesReference only (book value with convergence): BV/sh $11.79, ROE converges to ke
Discounted Future Market CapGrowth$13.091.71xyesRev $11.3B, growth -3% (input: historical growth; tapered), Terminal P/S: 0.9x / 1.0x / 1.2x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$8.322.69xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.79B × (1−21%) / WACC 4.9% → EPV (no growth)
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative$4.644.83xyesEBITDA $0.67B × sector EV/EBITDA 16.0x
FCF YieldEarnings$10.062.23xyesFCF $1251.0M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$7.602.95xyesSBC-adj FCF $1.13B (FCF $1.25B − SBC $0.12B) capitalized at Kₑ
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset$0.8725.74xyesBV $11.79 × (ROIC 0.4% / WACC 4.9%) (excluded from median)
P/Sales SectorRelative$87.920.25xyesRevenue $11.32B × sector P/S 4.0x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$7.4b
Net debt / NOPAT (after-tax)6.38x
Net debt / operating income (pre-tax)5.04x
Share count CAGR (dilution)0.3%
Burning cashno

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 13.5%); the trailing year was depressed.

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

Bull Case

Baxter is best read as a company in the middle of a reset, and the stage it is in changes how the numbers should be interpreted. The trailing income statement looks ugly, with reported operating income negative on restructuring and charges, but that trough is the symptom of a deliberate transformation, not the steady state. Baxter spent years overpaying for acquisitions, most notably Hillrom, and loading on debt to do it. The cleanup is now underway: in early 2025 it sold its Kidney Care business, now called Vantive, to Carlyle for $3.8 billion, and applied the proceeds directly to the debt that had been crushing the income statement. A company shedding a division to delever is choosing a leaner, more focused future, and the market is pricing the pain of the transition rather than the business on the other side of it.

The core that remains is a genuine medical-products franchise with recurring, consumable-driven demand. Baxter makes infusion pumps and the IV fluids that run through them, advanced surgical products, and hospital connectivity and monitoring tools, the kind of equipment that sits in every hospital and generates repeat consumable sales for years after the device is installed. On normalized, through-the-cycle margins, the business earns roughly $1.5 billion of operating income, and it generates over $1.2 billion of free cash flow. That cash is the engine of the turnaround, and management has pointed it squarely at debt reduction, targeting a net leverage ratio near 3x by the end of 2026.

The new leadership is the catalyst the bull case leans on. Andrew Hider took over as CEO in September 2025, brought in specifically for a background in industrial automation and operational efficiency, which is exactly the skill set a company with margin and cost problems needs. The valuation gives the turnaround a lot of room: at about 12 times mid-cycle operating income, the price sits below what even a steady decline in operating profit would warrant, in the lower half of the medical-device peer multiple range. The bet is that a focused, delevered Baxter under operations-minded management recovers its margins toward where this kind of franchise should earn, and the price is paying almost nothing for that recovery to happen.

Bear Case

The external variable with the most leverage on Baxter is regulatory and operational risk, because this is a medical-device maker whose products have to clear the FDA and stay clear of it. That risk is not hypothetical right now: the filing discloses that the company has "implemented a voluntary ship and installation hold in the U.S. and Canada, which remains ongoing" for its Novum large-volume infusion pump. A ship hold on a flagship product is a direct hit to revenue and a sign of quality issues that can take quarters to resolve, and the filing adds that "New or unintended uses of our products may also raise quality or safety issues." Baxter sells into hospitals worldwide, under the FDA and a dozen foreign regulators, and any of them can pause a product, force a recall, or delay an approval. For a company already struggling with margins, a regulatory setback is the kind of shock the thin guidance cannot absorb.

The debt turns that operational risk into a financial one. Net debt above $7 billion runs nearly five times normalized operating income, and the filing confirms the credit agreements carry "various covenants, including a maximum net leverage ratio." A leverage covenant is a tripwire: if earnings fall, the leverage ratio rises toward the cap even if the company makes no new borrowing, and breaching it can force renegotiation on worse terms. The whole deleveraging plan assumes margins recover and cash flow holds; if either slips, the company is delevering into a headwind, with less room to invest in the products that drive future growth.

The guidance itself is the bear's clearest evidence. Full-year 2026 adjusted EPS guidance of $1.85 to $2.05 came in well below the roughly $2.25 the market expected, and adjusted gross margins compressed by nearly 900 basis points on unfavorable product mix and rising logistics costs. That is not a company whose margins are quietly recovering; it is one telling investors the pressure is still building. Hospital customers are also under their own budget pressure, and tariffs on imported components add another cost line outside Baxter's control. The bear case is straightforward: a heavily indebted medical-products company with an active product hold, compressing margins, and below-consensus guidance is being asked by its lenders to delever at exactly the moment its earnings power is most in question. The cheap multiple is the market pricing real execution and regulatory risk, not handing out a bargain.

Valuation

Baxter cannot be valued on trailing earnings, because reported operating income is negative on restructuring charges. The price has to rest on what the business earns through a normal cycle, and on that normalized basis the market is paying about 12 times mid-cycle operating income, a multiple so low it sits below what even a 5% annual decline in operating profit would warrant. In the lower half of the medical-device peer range, the price is already discounting a business that struggles, not one that thrives.

The method disagreement reflects the distressed-but-recovering setup. Because trailing earnings and returns are negative, the earnings-power and asset-return lenses produce numbers that are not meaningful (an earnings-power read built on depressed normalized EBIT, and a return-on-book lens that divides by a near-zero return), so they should be read as reference points rather than valuations. What carries more weight are the cash-flow and revenue-based lenses: the exit-multiple cash-flow method and the discounted-future-market-cap method land above the price, crediting a recovery, while the zero-growth free-cash-flow lens lands below it. The honest read is that the price is supported only if Baxter's margins and cash flow recover; the methods that assume the current trough persists value it lower. This is a turnaround valuation, where the spread between the cash the business could generate and the cash it generates today is the whole question.

Solvency is where the risk concentrates and bounds the analysis. Net debt above $7 billion sits near five times normalized operating income, with interest coverage around 4.9 times and roughly $2 billion of liquid assets, and the credit agreements carry a maximum-net-leverage covenant. The Vantive sale and the resulting debt paydown were the first step, and management targets net leverage near 3x by year-end 2026. The most decisive point for the valuation is that the deleveraging and the margin recovery have to happen together: the price is cheap because the leverage leaves no margin for error, so the buyer is underwriting both a financial repair and an operational one, with an active product hold and below-consensus guidance as the evidence that neither is finished.

Catalysts

Baxter is mid-transformation, and the catalysts are a mix of completed repair and unresolved pressure. The defining move was the sale of the Kidney Care business, Vantive, to Carlyle for $3.8 billion in early 2025, with proceeds directed at the debt taken on for the Hillrom acquisition. The improvement in net interest expense from that debt reduction is now flowing through the income statement, the first concrete benefit of the deleveraging plan.

The forward catalyst is execution under new leadership. Andrew Hider became CEO in September 2025, brought in for an operational-efficiency background suited to Baxter's margin problem, and the capital priority is debt paydown toward a net-leverage target near 3x by year-end 2026. Each quarter's progress on margin and leverage is the read on whether the turnaround is taking hold. The guidance set the bar low: full-year 2026 adjusted EPS of $1.85 to $2.05, below expectations, with gross margins compressed nearly 900 basis points on product mix and logistics costs.

The operational overhang to watch is the Novum infusion pump. Baxter has a voluntary ship-and-installation hold on the pump in the U.S. and Canada that remains ongoing, a direct drag on revenue and a quality issue that needs resolution before the product can contribute fully. The next earnings reports, with the margin trajectory, the leverage ratio against the covenant, and any update on the pump hold, are the cleanest read on whether the focused, delevered Baxter the bull case envisions is actually emerging.

Peer Cohorts (Per Segment, With Filing Citations)

Medical Products & Therapies (reported)

Healthcare Systems & Technologies (reported)

Pharmaceuticals (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Baxter 2025-2026 disclosures · Baxter FY2026 guidance · Baxter FY2025 10-K · company financial data · Baxter capital allocation plan · Baxter leadership announcement, 2025 · Baxter FY2026 guidance and results · Baxter 2025 transaction disclosures · Baxter FY2026 results · Baxter leadership announcement and capital plan

View the full interactive BAX report on boothcheck